Vitamin D Therapy Market worth $4.14 billion by 2027, at a CAGR of...

Vitamin D Therapy Market worth $4.14 billion by 2027, at a CAGR of 11.60%

Posted 2023-05-08 12:31:28

According to a new market research report, "Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024", is expected to grow from USD 1.90 billion in 2019 to USD 4.14 billion by 2027, at a CAGR of 11.60% during the forecast period. The major factors driving the growth of this market include the growing awareness about vitamin D deficiency among consumers and the presence of a large target patient population worldwide.

By route of administration, the market is segmented into oral and parenteral routes of administration. The oral route of administration is expected to register the largest share and highest CAGR during the forecast period. This can be attributed to the ease of administration, better pharmacokinetic and pharmacodynamic activity, reduced chance of toxicity, increased patient compliance, and higher preference for the oral route.

The oral route of administration dominated the vitamin D therapy market in 2018

By route of administration, the vitamin D therapy market is segmented into oral and parenteral routes of administration. In 2018, the oral route accounted for the largest share of the market. The large share of this segment can be attributed to the ease of administration, better pharmacokinetic and pharmacodynamic activity, its economy (as compared to parenteral and topical routes), and higher preference for the oral route.

Osteoporosis held the largest share of the applications market in 2018

Based on applications, the vitamin D therapy market is segmented into osteoporosis, rickets, skin diseases, muscle weakness, autoimmune disorders, and other applications. In 2018, the osteoporosis segment accounted for the largest share of the vitamin D therapy market. The large share of this segment can be attributed to the increasing incidence of falls and fractures in senior adults due to the elevated level of parathyroid hormones and the poor absorption of calcium from their diets.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32540026

The Asia Pacific commanded the largest share of the vitamin D therapy market in 2018

The Asia Pacific dominated the vitamin D therapy market. The large share of this regional segment can be attributed to the increasing awareness about vitamin D deficiency, supportive government policies and programs for the implementation of vitamin D deficiency treatment plans in the region, heavy air pollution, sedentary lifestyles, increasing incidence of vitamin D deficiency, decreasing sun exposure, and rising malnutrition levels.

Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).